Clinical Trials: Page 100
-
Nektar secures $400M deal with Lilly for Phase 1 drug
Lilly liked what it saw in the immunological candidate, paying $150 million upfront to gain access to a compound Nektar discovered just over a year ago.
By Ned Pagliarulo • July 24, 2017 -
Prescribed Reading: Bolt-on deals for Sanofi
The big pharma tries to fill its pipeline, Vertex touts strong CF data and the FDA gives three approvals.
By Lisa LaMotta • July 21, 2017 -
Explore the Trendline➔
Getty Images
TrendlineNeuroscience drug development
Enthusiasm is running higher among drugmakers and investors for neuroscience drug development, buoyed by recent approvals of new Alzheimer’s, ALS and depression medicines.
By BioPharma Dive staff -
Ironwood touts positive data, but investors aren't sold
The company intends to move the 1,500 mg dose of IW-3718 into Phase 3 after lower doses missed primary outcome measures.
By Jacob Bell • July 20, 2017 -
Neurotrope stock tumbles again on Alzheimer's data
Sea-derived bryostatin-1 still isn't quite hitting the spot for Neurotrope in Alzheimer's disease.
By Suzanne Elvidge • July 20, 2017 -
Positive triple combo data sets up Vertex for big growth
The new data on its cystic fibrosis treatments lifted shares more than 20%, adding billions to the company's market capitalization.
By Jacob Bell • July 19, 2017 -
Abeona set to fly into Phase 3 after FDA chat
Following FDA guidance, Abeona is scooting EB-101 straight into Phase 3 for "butterfly disease."
By Suzanne Elvidge • July 19, 2017 -
Elizabeth Regan/BioPharma Dive
CymaBay touts positive seladelpar liver results
Results from a lower dose study showed efficacy without the liver toxicity issues, driving up shares of the stock.
By Suzanne Elvidge • July 18, 2017 -
New data from Alzheon shows long-term benefit for Alzheimer's
APOE4 homozygotes who received higher doses of Alzheon's candidate over multiple years had "sustained cognitive and functional benefits."
By Jacob Bell • July 17, 2017 -
Deep Dive
5 trends shaping Alzheimer's drug development
Almost all Alzheimer’s drugs have failed. But pharma continues to invest millions in hopes of finding a hit, motivated by market opportunity and armed with lessons learned.
By Ned Pagliarulo • July 17, 2017 -
Deep Dive
What do we know about the amyloid theory for Alzheimer's?
A growing knowledge of the science behind the disease is allowing researchers to better test potential therapies.
By Jacob Bell • July 17, 2017 -
Genentech BD: Alzheimer's continues to be a priority
Genentech's Tom Zioncheck sat down with BioPharma Dive to talk about the big biotech's work in Alzheimer's disease.
By Lisa LaMotta • July 17, 2017 -
Deep Dive
Alzheimer's drug developers still hoping for a homer
The unmet need presented by the ever-growing patient population coupled with better science has the Alzheimer's disease pipeline filling up.
By Malorye Allison Branca • July 17, 2017 -
Prescribed Reading: Rumors, blood and history in the making
Rumors swirl about a new CEO at Teva, hemophilia drugs are getting exciting and the first CAR-T therapy could be coming.
By Lisa LaMotta • July 14, 2017 -
VBI Vaccines takes a shot at HBV Phase 3
Third-generation vaccines could have a stab at the harder-to-protect older population.
By Suzanne Elvidge • July 13, 2017 -
FDA panel unanimously backs approval of Novartis CAR-T
If approved later this year for an aggressive type of leukemia, Novatis' tisagenlecleucel would be the first CAR-T therapy OK'd for commercial use.
By Ned Pagliarulo • July 12, 2017 -
FDA
Woodcock: We need better biomarkers
The CDER director says precision medicine has come a long way, but biomarkers will bring the advances even further.
By Lisa LaMotta • July 12, 2017 -
Kadmon ROCKing some positive results
The biotech's ROCK2 inhibitor cut steroid use post-transplant for two-thirds of patients.
By Suzanne Elvidge • July 12, 2017 -
BioMarin, Spark, raising the stakes for hemophilia
The hemophilia market heats up as exciting technology, including gene therapy and RNA interference, are changing the the disease landscape.
By Lisa LaMotta • July 12, 2017 -
Sponsored by PPD Laboratories
There's an app for that: Busy investigators can now manage clinical trials on the go
Tapping into a ubiquitous trend among businesses, one major CRO lab is developing an app to communicate more efficiently with its clients, investigators and clinical trial managers.
By Roni Robbins • July 11, 2017 -
FDA lifts clinical hold on Concert drug
Concert can now restart testing of its hair loss drug under an amended protocol.
By Suzanne Elvidge • July 11, 2017 -
Arena pumps out positive results for hypertension drug
Ralinepag improved pulmonary vascular resistance in a Phase 2 study, giving Arena a lift in its bid to pivot away from its disappointing weight-loss franchise.
By Jacob Bell • July 10, 2017 -
Safety issues for Novartis CAR-T therapy main focus of FDA
Documents released ahead of a key advisory meeting Wednesday show the agency is primarily concerned with the safety risks of what could be the first CAR-T therapy approved.
By Ned Pagliarulo • July 10, 2017 -
Prescribed Reading: I/O is the only game in town
Immuno-oncology dominates dealmaking, clinical trial data and regulatory action.
By Lisa LaMotta • July 7, 2017 -
Further support for Opdivo as it beats out Yervoy
Bristol-Myers Squibb continues to build the case that the PD-1 inhibitor is a better option than its older immunotherapy.
By Suzanne Elvidge • July 6, 2017 -
PTC and Roche report solid data for Spinraza rival
The biotech and its big pharma partner reported promising preliminary data for their spinal muscular atrophy drug at a conference over the weekend.
By Lisa LaMotta • July 5, 2017
Previous
